IPASS reshaped global lung cancer guidelines
2009In 2009, the IPASS trial led by Academician Tony Mok was published in NEJM, establishing the targeted-therapy paradigm for EGFR-mutant lung cancer worldwide.
Back to home
Public Teaching Hospital · Internationally Accredited
Prince of Wales Hospital (CUHK Teaching Hospital)
Lung cancerColorectal cancerLiver cancerNasopharyngeal cancer
Established
1984
Beds
1,800+
Annual Volume
50,000+
Hong Kong
A global hub for lung cancer research led by Prof. Tony Mok; the IPASS study set the worldwide standard for EGFR-mutant lung cancer; gateway to international trials and Greater Bay Area cross-border care.
About the Hospital
Prince of Wales Hospital is the principal teaching hospital of The Chinese University of Hong Kong and a major public hospital under the Hong Kong Hospital Authority. Anchored by the CUHK Faculty of Medicine, it holds world-class academic influence in oncology — especially lung cancer research.
Research teams represented by Academician Tony Mok (Shu-Kam Mok) have repeatedly led international multicenter trials that changed global lung cancer practice, making the hospital a key bridge between Chinese and international oncology research.
Hospital Strengths
01World-class lung cancer research hub
Landmark trials led by Academician Tony Mok — including IPASS — established the targeted-therapy paradigm for EGFR-mutant lung cancer and reshaped global guidelines.
02International standards and language environment
Hong Kong’s healthcare system follows international standards, and its bilingual (Chinese-English) environment eases communication and medical record recognition for international patients.
03A bridge between mainland and international care
Close academic ties with top mainland cancer centers enable two-way referral coordination between Hong Kong and the mainland for international patients.
Key Departments
Clinical OncologyMedical OncologyThoracic SurgeryRadiation OncologyPathology
Coordinated Treatment Directions
- 01Precision lung cancer care and clinical research
- 02International-standard multidisciplinary oncology care
- 03Two-way referral coordination between Hong Kong and mainland
Officially Reported Treatment Milestones
AURA3 established osimertinib as standard of care
2017In 2017, the AURA3 trial led by Academician Tony Mok was published in NEJM, establishing osimertinib as the standard of care for EGFR T790M-positive lung cancer.
Accreditations & Platforms
- CUHK teaching hospital; home of the Sir YK Pao Centre for Cancer
- Core site for international multicenter trials (e.g., IPASS)